vs
UNITED STATES LIME & MINERALS INC（USLM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是UNITED STATES LIME & MINERALS INC的1.4倍（$127.1M vs $87.9M），再鼎医药同比增速更快（17.1% vs 9.8%），UNITED STATES LIME & MINERALS INC自由现金流更多（$25.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.8%）
美国石灰矿产公司是总部位于美国的自然资源企业，主营高钙石灰、白云石石灰、石灰石及相关矿产制品，客户覆盖基建、钢铁制造、农业土壤改良、环保排放治理、工业加工等领域，业务主要辐射北美市场。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
USLM vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$87.9M
营收增速更快
ZLAB
高出7.3%
9.8%
自由现金流更多
USLM
多$52.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.9M | $127.1M |
| 净利润 | $30.5M | — |
| 毛利率 | 48.0% | 51.0% |
| 营业利润率 | 41.0% | -54.6% |
| 净利率 | 34.7% | — |
| 营收同比 | 9.8% | 17.1% |
| 净利润同比 | 13.2% | — |
| 每股收益（稀释后） | $1.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收USLMZLAB
| Q4 25 | $87.9M | $127.1M | ||
| Q3 25 | $102.0M | $115.4M | ||
| Q2 25 | $91.5M | $109.1M | ||
| Q1 25 | $91.3M | $105.7M | ||
| Q4 24 | $80.1M | $108.5M | ||
| Q3 24 | $89.4M | $101.8M | ||
| Q2 24 | $76.5M | $100.1M | ||
| Q1 24 | $71.7M | $87.1M |
净利润USLMZLAB
| Q4 25 | $30.5M | — | ||
| Q3 25 | $38.8M | $-36.0M | ||
| Q2 25 | $30.8M | $-40.7M | ||
| Q1 25 | $34.1M | $-48.4M | ||
| Q4 24 | $27.0M | — | ||
| Q3 24 | $33.4M | $-41.7M | ||
| Q2 24 | $26.1M | $-80.3M | ||
| Q1 24 | $22.4M | $-53.5M |
毛利率USLMZLAB
| Q4 25 | 48.0% | 51.0% | ||
| Q3 25 | 51.2% | 59.5% | ||
| Q2 25 | 45.8% | 60.6% | ||
| Q1 25 | 50.6% | 63.6% | ||
| Q4 24 | 44.3% | 61.5% | ||
| Q3 24 | 48.2% | 64.1% | ||
| Q2 24 | 45.5% | 64.9% | ||
| Q1 24 | 42.7% | 61.4% |
营业利润率USLMZLAB
| Q4 25 | 41.0% | -54.6% | ||
| Q3 25 | 45.3% | -42.3% | ||
| Q2 25 | 39.0% | -50.3% | ||
| Q1 25 | 43.7% | -53.3% | ||
| Q4 24 | 38.8% | -62.6% | ||
| Q3 24 | 42.6% | -66.6% | ||
| Q2 24 | 39.1% | -76.0% | ||
| Q1 24 | 35.9% | -80.7% |
净利率USLMZLAB
| Q4 25 | 34.7% | — | ||
| Q3 25 | 38.0% | -31.2% | ||
| Q2 25 | 33.7% | -37.3% | ||
| Q1 25 | 37.4% | -45.8% | ||
| Q4 24 | 33.7% | — | ||
| Q3 24 | 37.3% | -40.9% | ||
| Q2 24 | 34.0% | -80.2% | ||
| Q1 24 | 31.3% | -61.4% |
每股收益（稀释后）USLMZLAB
| Q4 25 | $1.06 | $-0.05 | ||
| Q3 25 | $1.35 | $-0.03 | ||
| Q2 25 | $1.07 | $-0.04 | ||
| Q1 25 | $1.19 | $-0.04 | ||
| Q4 24 | $-2.20 | $-0.09 | ||
| Q3 24 | $1.16 | $-0.04 | ||
| Q2 24 | $0.91 | $-0.08 | ||
| Q1 24 | $3.92 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $371.1M | $689.6M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $630.8M | $715.5M |
| 总资产 | $681.0M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资USLMZLAB
| Q4 25 | $371.1M | $689.6M | ||
| Q3 25 | $349.5M | $717.2M | ||
| Q2 25 | $319.9M | $732.2M | ||
| Q1 25 | $300.6M | $757.3M | ||
| Q4 24 | $278.0M | $779.7M | ||
| Q3 24 | $255.0M | $616.1M | ||
| Q2 24 | $222.5M | $630.0M | ||
| Q1 24 | $207.0M | $650.8M |
总债务USLMZLAB
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
股东权益USLMZLAB
| Q4 25 | $630.8M | $715.5M | ||
| Q3 25 | $602.3M | $759.9M | ||
| Q2 25 | $563.3M | $791.7M | ||
| Q1 25 | $532.2M | $810.8M | ||
| Q4 24 | $497.7M | $840.9M | ||
| Q3 24 | $474.2M | $667.7M | ||
| Q2 24 | $441.1M | $704.2M | ||
| Q1 24 | $415.3M | $762.2M |
总资产USLMZLAB
| Q4 25 | $681.0M | $1.2B | ||
| Q3 25 | $652.8M | $1.2B | ||
| Q2 25 | $607.4M | $1.2B | ||
| Q1 25 | $585.3M | $1.2B | ||
| Q4 24 | $543.2M | $1.2B | ||
| Q3 24 | $521.8M | $985.3M | ||
| Q2 24 | $484.2M | $987.4M | ||
| Q1 24 | $464.0M | $988.4M |
负债/权益比USLMZLAB
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $25.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 29.2% | -21.0% |
| 资本支出强度资本支出/营收 | 22.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.49× | — |
| 过去12个月自由现金流最近4个季度 | $102.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流USLMZLAB
| Q4 25 | $45.6M | $-26.0M | ||
| Q3 25 | $45.9M | $-32.0M | ||
| Q2 25 | $34.0M | $-31.0M | ||
| Q1 25 | $39.4M | $-61.7M | ||
| Q4 24 | $38.6M | $-55.8M | ||
| Q3 24 | $39.0M | $-26.8M | ||
| Q2 24 | $21.2M | $-42.2M | ||
| Q1 24 | $27.2M | $-90.1M |
自由现金流USLMZLAB
| Q4 25 | $25.7M | $-26.7M | ||
| Q3 25 | $31.3M | $-35.0M | ||
| Q2 25 | $20.8M | $-33.9M | ||
| Q1 25 | $24.6M | $-63.2M | ||
| Q4 24 | $27.6M | $-58.4M | ||
| Q3 24 | $33.9M | $-28.2M | ||
| Q2 24 | $16.8M | $-42.9M | ||
| Q1 24 | $20.3M | $-91.1M |
自由现金流率USLMZLAB
| Q4 25 | 29.2% | -21.0% | ||
| Q3 25 | 30.7% | -30.4% | ||
| Q2 25 | 22.7% | -31.1% | ||
| Q1 25 | 26.9% | -59.9% | ||
| Q4 24 | 34.4% | -53.8% | ||
| Q3 24 | 37.9% | -27.7% | ||
| Q2 24 | 21.9% | -42.9% | ||
| Q1 24 | 28.4% | -104.5% |
资本支出强度USLMZLAB
| Q4 25 | 22.6% | 0.5% | ||
| Q3 25 | 14.4% | 2.6% | ||
| Q2 25 | 14.5% | 2.6% | ||
| Q1 25 | 16.3% | 1.5% | ||
| Q4 24 | 13.8% | 2.4% | ||
| Q3 24 | 5.8% | 1.3% | ||
| Q2 24 | 5.7% | 0.7% | ||
| Q1 24 | 9.5% | 1.1% |
现金转化率USLMZLAB
| Q4 25 | 1.49× | — | ||
| Q3 25 | 1.18× | — | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 0.81× | — | ||
| Q1 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
USLM
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
